Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 64 EBITDA Margin % is 19.16% as of Jun. 2026, which is 33% below its 10-year median of 28.45. GuruFocus rates ROCO:6879 with a GF Score™ of 64/100 and a GF Value™ of NT$35.84 (Fairly Valued). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Tci Gene ranks better than 81.42% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tci Gene's EBITDA for the
six
months ended in Jun. 2026 was NT$22.9 Mil. Tci Gene's Revenue for the
six
months ended in Jun. 2026 was NT$119.5 Mil. Therefore, Tci Gene's EBITDA margin for the quarter that ended in Jun. 2026 was 19.16%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tci Gene EBITDA Margin % Related Terms
Tci Gene EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tci Gene's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Tci Gene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tci Gene's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tci Gene (ROCO:6879) has a EBITDA Margin % of 19.16% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tci Gene and its competitors. This is 33% below median its historical median of 28.45. Over the past decade, Tci Gene's EBITDA Margin % has ranged from 7.76 to 35.89. According to the industry distribution chart, Tci Gene ranks #175 out of 942 companies in the Biotechnology industry, placing it in the top 18.6%.
Is Tci Gene's EBITDA Margin % too high?
Tci Gene's current EBITDA Margin % of 19.16% is 33% below median its 10-year median of 28.45. Over the past 10 years, this metric has ranged from a low of 7.76 to a high of 35.89. Based on the distribution chart, Tci Gene ranks #175 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #175 out of 942 companies for EBITDA Margin %. This places Tci Gene in the top 19% of its industry — outperforming the majority of peers. Historically, Tci Gene's own EBITDA Margin % has ranged from 7.76 to 35.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tci Gene and its competitors. Tci Gene's current EBITDA Margin % is 19.16%, which is 33% below median its own 10-year median of 28.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Fairly Valued. The stock's GF Value™ is NT$35.84, compared to a current price of NT$34.00 — trading 5.1% below its estimated fair value. The current EBITDA Margin % is 19.16%, which is 33% below median its 10-year median of 28.45. Tci Gene's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current EBITDA Margin % is 19.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$34.00 is trading 5.1% below its estimated GF Value™ of NT$35.84.
GuruFocus considers Tci Gene to be Fairly Valued.
Key valuation signals for ROCO:6879:
EBITDA Margin %: 19.16% (33% below median its 10-year median of 28.45)
GF Value™: NT$35.84 vs. price of NT$34.00 (5.1% below fair value)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
64GF Score
Get the complete analysis for ROCO:6879
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
